Skip Navigation

European Heart Journal 1988 9(4):373-379;
Copyright © 1988 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by LINDVALL, K.
Right arrow Articles by SJÖGREN, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LINDVALL, K.
Right arrow Articles by SJÖGREN, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 The European Society of Cardiology

Efficacy and tolerability of transdermal nitroglycerin in heart failure

A noninvasive placebo controlled double-blind cross over study

K. LINDVALL*,, S. V. ERIKSSON*, L. LAGERSTRAND{dagger} and A. SJÖGREN*

*Departments of Medicine, Karolinska Institute, Danyeryd Hospital Stockholm, Sweden
{dagger}Department of Clinical Physiology, Karolinska Institute, Danderyd Hospital Stockholm, Sweden

Received 4 June 1986; revised 9 October 1987; .

Address for reprints: K. Lindvall, M.D. Med Dept I, Division of Cardialogy, Södersjukhuset, 10064, Stockholm, Sweden.

Abstract

The efficacy of transdermal nitroglycerin was investigated in 18 patients with moderate to severe congestive heart failure in a placebo-controlled, double-blind, crossover study. Treatment periods were of four weeks, following a one week dose titration period during which the maximum tolerated dose within the range of 5–15 mg was estimated. Therapeutic effects were evaluated by clinical examination (NYHA class), treadmill exercise, echocardiography and patient subjective scaling of general well being, cardiac symptoms and dyspnoea.

Both patient and investigator analogue scaling of general well being showed improved scores indicating an improvement throughout the study. This tendency was even more marked when comparing inclusion values with those after each treatment period (P<0.05). However, when comparing values before with those after each treatment period, only the investigator scaling of heart failure level proved significantly higher after the placebo period (P<0.05). No other findings of significance were observed. We conclude that transdermal nitroglycerin given in the present doses over four weeks fails to improve the clinical situation in patients with moderate to severe congestive heart failure.

Key Words: Nitroglycerin • transdermal • echocardiography • heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.